Events & presentations

Upcoming Events
Date Event Details Remind Me
Jun 1–5, 2018
ASCO Annual Meeting, Chicago, IL, US

Please see our download library for links to abstracts. 

Email

ASCO Annual Meeting, Chicago, IL, US

Remind Me

Please sign up for Email alerts.


Jun 12–14, 2018
Goldman Sachs 39th Annual Global Healthcare Conference, Rancho Paalos Verdes, CA, US
Email

Goldman Sachs 39th Annual Global Healthcare Conference, Rancho Paalos Verdes, CA, US

Remind Me

Please sign up for Email alerts.


Jun 14–17, 2018
23rd Congress of EHA, Stockholm, Sweden

Please see our download library for links to abstracts. 

Email

23rd Congress of EHA, Stockholm, Sweden

Remind Me

Please sign up for Email alerts.


Jun 19–20, 2018
Citi 2018 European Healthcare Conference, London, US
Email

Citi 2018 European Healthcare Conference, London, US

Remind Me

Please sign up for Email alerts.


Aug 8, 2018
After 5:00 PM CET
Publication of the Interim Report for the first half 2018
Email

Publication of the Interim Report for the first half 2018

Remind Me

Please sign up for Email alerts.


Nov 14, 2018
After 5:00 PM CET
Publication of the Interim Report for the first nine months 2018
Email

Publication of the Interim Report for the first nine months 2018

Remind Me

Please sign up for Email alerts.


Archived Events
Date Event Details
May 21–23, 2018
UBS Global Healthcare Conference, New York, NY, US
May 9, 2018
5:00 PM
Interactive Q&A Session with Genmab's CEO
May 9, 2018
Deutsche Bank's 43rd Annual Healthcare Conference, Boston, MA, US
May 8, 2018
6:00 PM CET
First Quarter 2018 Conference Call
May 8, 2018
After 5:00 PM CET
Publication of the Interim Report for the first quarter 2018
Apr 18, 2018
Kempen Life Sciences Conference, Amsterdam, The Netherlands
Apr 10, 2018
Annual General Meeting 2018
Feb 27, 2018
Credit Suisse Healthcare Conference, London, UK
Feb 26, 2018
Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors
Feb 22, 2018
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
Feb 21, 2018
6:00 PM CET
Full Year 2017 Financial Results Conference Call
Feb 21, 2018
After 5:00 PM CET
Publication of the Annual Report for 2017
Jan 10, 2018
2:00 PM PT
36th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US

CEO, Jan van de Winkel, Ph.D., will present a company update at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco at 2:00 PM PST on January 10, 2018 (11:00 PM CET).

Dec 14, 2017
DNB Nordic Healthcare Conference 2017, Oslo, Norway
Dec 11, 2017
8:00 PM ET
2017 R&D Update, Atlanta, Georgia, US

Genmab hosted a 2017 R&D Update on December 11 in Atlanta, Georgia. The meeting included the presentation of daratumumab data presented at the 2017 American Society of Hematology Annual Meeting (December 9-12) as well as a discussion of Genmab's product pipeline, 2017 progress and key goals for 2018.To listen to the archived webcast, click here. To download the presentation, click hereThis meeting was not an official program of the ASH Annual meeting. 

Dec 9–12, 2017
59th Annual American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA, US

Visit the Download Library to access presentations and posters after they have been presented at the ASH meeting

Links to Abstracts

Daratumumab

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma (SMM): CENTAURUS, a Randomized, Open-label, Multicenter Phase II Study

Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of POLLUX

Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase Ib Study

Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in CASTOR

Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results of an Open-label, Phase I/II Study

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001): An Open-label, Phase Ib Study

Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone Versus  Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) in Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients with Multiple Myeloma

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS

Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-label, Phase Ib Study

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX, a Phase III Randomized Study

Daratumumab, Bortezomib and Dexamethasone  (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR

Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial

Cost-effectiveness of Daratumumab  Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial

Ofatumumab
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma After Prior Rituximab

Dec 6–7, 2017
Citi 2017 Global Healthcare Conference, New York, NY, US
Nov 30, 2017
dbAccess Pharmaceutical and Healthcare Corporate Day, London, UK
Nov 16–17, 2017
Bryan, Garnier & Co 5th Annual Healthcare Conference, Paris, France
Nov 15–16, 2017
Jefferies 2017 London Healthcare Conference, London, UK
Nov 9, 2017
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
Nov 8, 2017
6:00 PM CET
Third Quarter 2017 Conference Call
Nov 4–7, 2017
2017 International Meeting of The European Society of Gynaecological Oncology (ESGO), Vienna, Austria
Sep 14, 2017
Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK
Sep 12, 2017
2:55 PM ET
Morgan Stanley Global Healthcare Conference, New York, NY, US
Sep 8–12, 2017
ESMO 2017 Congress, Madrid, Spain
Aug 10, 2017
2:00 PM CET
Interactive Q&A Session with Genmab's CEO
Aug 9, 2017
6:00 PM CET
Second Quarter 2017 Conference Call